ALSO NOTED: Tarceva gets Japan's nod; FDA blesses Novartis arthritis remedy;

> Japanese drug regulators approved Roche's lung cancer drug Tarceva, made by OSI Pharmaceuticals. Release

> The FDA has given its blessing to Novartis' Voltaren, a topical non-steroidal anti-inflammatory gel for relief of osteoarthritis pain; systemic absorption is 94 percent less than with oral NSAID formulations, the company said. Release

> Solvay has inked a deal with Abbott Laboratories to jointly promote Abbott's combination cholesterol drug Simcor, which puts simvastatin and Niaspan in one pill. Release

> In a major setback for Dor BioPharma, the FDA has issued a not approvable letter for the company's lead drug orBec, a treatment for gastrointestinal Graft-versus-Host disease (GI GVHD). Report

> Ranbaxy, one of India's largest drug makers and a dominant force in the generic drugs business, is spinning off its R&D unit that will develop new medicines. Report

And Finally... Cancer death rates, part II: They're down overall, but certain cancers, such as myeloma, are on the uptick. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.